| a bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic ebola viruses in rhesus macaques. | the 2013-2016 ebola outbreak in west africa led to accelerated efforts to develop vaccines against these highly virulent viruses. a live, recombinant vesicular stomatitis virus-based vaccine has been deployed in outbreak settings and appears highly effective. vaccines based on replication-deficient adenovirus vectors either alone or in combination with a multivalent modified vaccinia ankara (mva) ebola vaccine also appear promising and are progressing in clinical evaluation. however, the ability ... | 2020 | 32075939 |
| efficacy of human monoclonal antibody monotherapy against bundibugyo virus infection in nonhuman primates. | the 2013-2016 ebola virus disease (evd) epidemics in west africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. monoclonal antibodies (mabs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. data about efficacy of human mab monotherapy against filovirus infections in preclinical nonhuman primate models are limited. | 2018 | 29982718 |
| bundibugyo ebolavirus survival is associated with early activation of adaptive immunity and reduced myeloid-derived suppressor cell signaling. | ebolaviruses bundibugyo virus (bdbv) and ebola virus (ebov) cause fatal hemorrhagic disease in humans and nonhuman primates. while the host response to ebov is well characterized, less is known about bdbv infection. moreover, immune signatures that mediate natural protection against all ebolaviruses remain poorly defined. to explore these knowledge gaps, we transcriptionally profiled bdbv-infected rhesus macaques, a disease model that results in incomplete lethality. this approach enabled us to ... | 2021 | 34372693 |